Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics, Inc. (former Nasdaq: SAGE) is a Cambridge, Massachusetts-based biopharmaceutical company focused on brain health, with a particular emphasis on postpartum depression. The company reports that it developed the only two FDA-approved treatments indicated for postpartum depression and highlights ZURZUVAE (zuranolone), described as the first-and-only oral treatment for adults with postpartum depression and, in some communications, as a once-daily 14-day oral treatment.
The news flow around Sage has centered on several themes. One major area is commercial updates for ZURZUVAE, including collaboration revenue recognized under its agreement with Biogen, prescription shipment trends for women with postpartum depression, prescriber behavior among obstetrician-gynecologists, and payer coverage metrics. Regular quarterly earnings releases have discussed revenue from ZURZUVAE, other collaboration revenue, research and development spending, selling, general and administrative expenses, restructuring charges, and cash runway expectations.
Another recurring topic is Sage’s research and development pipeline. Company news has described progress with SAGE-319, an extrasynaptic-preferring GABAA receptor positive allosteric modulator being studied for behavioral symptoms associated with certain neurodevelopmental disorders, along with preclinical NMDA receptor negative allosteric modulator programs SAGE-817 and SAGE-039, and evaluation of potential indications for SAGE-324, including seizures in developmental and epileptic encephalopathies.
Corporate and strategic developments are also prominent in Sage’s news. Releases have covered a strategic alternatives review, unsolicited acquisition proposals, and, ultimately, the definitive agreement and subsequent completion of an acquisition by Supernus Pharmaceuticals, Inc. Investors reviewing SAGE-related news can use this page to follow historical earnings announcements, pipeline updates, leadership changes, strategic reviews, and the steps that led to Sage becoming a wholly owned subsidiary of Supernus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sage Therapeutics will host a live webcast on May 2, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and recent business updates. This event will be accessible via the Investor page on Sage’s website. A replay of the webcast will be available for 30 days post-event.
Sage Therapeutics focuses on advancing brain health solutions, committed to developing life-changing medicines for brain health. More information about their mission can be found on their website.
Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company focused on brain health, announced its participation in the Stifel 2023 CNS Days on March 29, 2023, at 11:00 a.m. ET. The presentation will be available via live webcast on Sage's investor page. A replay will be accessible for 30 days following the event. Sage's mission is to develop transformative therapies for brain health, aiming to empower individuals to thrive. For more details, visit www.sagerx.com.
Sage Therapeutics, Inc. (NASDAQ: SAGE) has appointed Jessica Federer to its Board of Directors. With a strong background in digital health and innovation, Federer aims to enhance the company's growth in maternal mental health care. She previously served as the first Chief Digital Officer for Bayer AG, where she shaped global digital strategy. Federer expressed her commitment to redefining brain health treatment, highlighting the potential of data strategies in this area. CEO Barry Greene noted her patient-first approach aligns with Sage's core values and ambitions. This strategic appointment could drive future growth for the company.
Sage Therapeutics (SAGE) and Biogen (BIIB) announced that the FDA will not convene an advisory committee to discuss the New Drug Application for zuranolone, a treatment for major depressive disorder (MDD) and postpartum depression (PPD). This investigational drug has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) action date set for August 5, 2023. Zuranolone is part of clinical programs LANDSCAPE and NEST, which include several studies across thousands of participants. The companies remain optimistic about zuranolone's potential, but there are inherent risks and uncertainties in drug approval processes.
Sage Therapeutics (NASDAQ: SAGE) will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 10:30 a.m. ET in Boston, MA. Investors can access the live webcast on Sage's investor page, with a replay available for 30 days after the event. Sage Therapeutics focuses on pioneering brain health solutions aimed at delivering transformative medicines, enhancing the quality of life for individuals. For further details, visit www.sagerx.com.